- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06278337
X-linked Moesin Associated Immunodeficiency (X-MAIDReg)
Etude Multicentrique Internationale rétrospective Des Patients Atteints de déficit Immunitaire associé à la moésine lié au Chromosome X (X Maid Pour X-linked Moesin Associated Immunodeficiency)
Moesin deficiency was initially described in 7 male participants aged 4 to 69 years and is characterized by lymphopenia of the 3 lineages and moderate neutropenia. Genetically, 6 out of 7 participants had the same missense mutation in the moesin gene located on the X chromosome. The 7th patient has a mutation leading to the premature introduction of a STOP codon into the protein.Clinically the 7 participants with X-linked moesin-associated immunodeficiency all presented with recurrent bacterial infections of the respiratory, gastrointestinal or urinary tracts, and some had severe varicella.Therapeutically, in the absence of a molecular diagnosis and due to his SCID-like phenotype, one patient was treated with geno-identical hematopoietic stem cell transplantation . The remaining are untreated or treated with immunoglobulin substitution and/or prophylactic antibiotics.
Since this study, the moesin gene has been integrated into DNA chips used for the molecular diagnosis of immune deficiencies in several countries. Physicians in Canada, the United States, Japan, South Africa and Europe have contacted us with a total of 16 known participants to date. Because of their very low severe, uncontrolled CMV infection and the absence of treatment recommendations, two 2 American participants were treated with allogeneic transplantation with severe post-transplant complications (1), and one of the participants died as a result of the transplant. Management of XMAID participants therefore varies widely from country to country, depending on age at diagnosis and clinical picture. It ranges from no treatment treatment (associated with recurrent infections and skin manifestations), IgIv substitution and/or antibiotic prophylaxis antibiotic prophylaxis, with low toxicity and apparent efficacy, and allogeneic transplantation, with all the risks risks involved (graft-related toxicity, graft versus host, disease, rejection, risk of infection). The Investigators therefore feel it is important to review the diagnosis, clinical presentation and management of X-MAID participants. The study the investigator propose will enable to understand the presentation of X-MAID participants, establish guidelines and provide the best treatment for each patient according to his or her clinical picture
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Isabelle ANDRE, Doctor
- Phone Number: 01 42 75 43 37
- Email: isabelle.andre@inserm.fr
Study Locations
-
-
-
Brisbane, Australia, 4001
- Not yet recruiting
- Genomic Research Centre, School of Biomedical Sciences Institute of Health and Biomedical Innovation
-
Contact:
- Lyn Griffith, Pr
-
-
-
-
-
Bruxelles, Belgium, 1020
- Not yet recruiting
- Hôpital Universitaire de la Reine Fabiola
-
Contact:
- Catherine Heijmans, Doctor
-
-
-
-
-
Paris, France, 75015
- Recruiting
- Hopital Necker
-
Contact:
- Benedicte NEVEN
-
Rennes, France, 35000
- Recruiting
- CHU Rennes, CNRS UMR 629
-
Contact:
- Virginie Gandemer, Doctor
-
Saint-Étienne, France, 42270
- Not yet recruiting
- CHU St Etienne Hôpital Nord
-
Contact:
- Jean-Louis STEPHAN, Doctor
-
-
-
-
-
Bunkyō-Ku, Japan, 1138510
- Not yet recruiting
- Tokyo Medical and Dental University (TMDU)
-
Contact:
- Kohsuke Imai, Pr
-
-
-
-
-
Rotterdam, Netherlands
- Not yet recruiting
- Departments of Internal Medicine and Immunology
-
Contact:
- Virgil Dalm
-
-
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- Not yet recruiting
- National Institutes of Health
-
Contact:
- Luigi Notarangelo, Doctor
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19050
- Not yet recruiting
- Perelman School of medecine
-
Contact:
- Jennifer Heimall, Pr
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02912
- Not yet recruiting
- Brown University
-
Contact:
- Anthony Hayward
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male patient with a mutation in the MOESIN gene (MSN)
- No objection to the collection of personal health data
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The main objective
Time Frame: through study completion, and average 3 years
|
The main objective is to study the clinical results of the different therapeutic options applied to X-MAID patients, and to investigate whether there is a correlation between treatment responses and mutation position
|
through study completion, and average 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary objectives1
Time Frame: through study completion, and average 3 years
|
Circumstances of genetic diagnosis: at what age are these patients diagnosed, and by what means?
(role of prenatal screening).
|
through study completion, and average 3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
secondary objectives 2
Time Frame: through study completion, and average 3 years
|
What is the state of their immune system and, depending on this state, the CID or SCID classification of the disease.
|
through study completion, and average 3 years
|
secondary objective 3
Time Frame: All the patients are male. As a result of their immune deficiency, patients suffer from recurrent bacterial infections of the respiratory, digestive and urinary tracts, as well as, in some cases, skin manifestations such as eczema, alopecia and molluscum
|
What are the clinical manifestations of the disease (cutaneous, infectious, autoimmune)?
|
All the patients are male. As a result of their immune deficiency, patients suffer from recurrent bacterial infections of the respiratory, digestive and urinary tracts, as well as, in some cases, skin manifestations such as eczema, alopecia and molluscum
|
secondary objectives 4
Time Frame: Among patients diagnosed in the first years of life, none showed developmental defects.
|
What impact does the disease have on their development?
|
Among patients diagnosed in the first years of life, none showed developmental defects.
|
secondary objective 5
Time Frame: Treatments range from no prophylaxis at all to antibiotic prophylaxis, with or without immunoglobulin therapy, granulocyte-colony-stimulating factor therapy or hematopoietic stem cell allograft.
|
What are the treatments and their consequences?
|
Treatments range from no prophylaxis at all to antibiotic prophylaxis, with or without immunoglobulin therapy, granulocyte-colony-stimulating factor therapy or hematopoietic stem cell allograft.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Isabelle ANDRE, doctor, Institut National de la Santé Et de la Recherche Médicale, France
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C19-35
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections
-
International Centre for Diarrhoeal Disease Research...Centers for Disease Control and PreventionNot yet recruitingMeasles | Rubella | Cholera | Typhoid
-
MJM BontenJanssen Research & Development, LLC; Innovative Medicines InitiativeCompletedE.Coli InfectionsUnited States, United Kingdom, Canada, France, Germany, Italy, Japan, Spain
-
PfizerCompletedGroup B Streptococcus InfectionsUnited States, South Africa, United Kingdom
-
GlaxoSmithKlineActive, not recruitingInfections, MeningococcalFinland, Poland, Spain, United Kingdom, Germany, South Africa, Dominican Republic, Israel, Honduras
-
PfizerCompletedInfections, MeningococcalAustralia, Canada, Czechia, Panama, South Africa, Turkey
-
GlaxoSmithKlineCompletedInfections, MeningococcalFinland
-
PfizerCompletedInfections, MeningococcalPhilippines
-
GlaxoSmithKlineCompletedInfections, MeningococcalUnited States, Finland, Poland
-
GlaxoSmithKlineCompleted
Clinical Trials on genetic restrospective study
-
University Hospital, Strasbourg, FranceUnknown
-
University Hospital, Strasbourg, FranceUnknown
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Cardiology Research UBCJohn GB Mancini, MD; Karin Humphries, DScRecruiting
-
Rennes University HospitalIntergroupe Francophone du MyelomeTerminatedMonoclonal Gammopathy of Undetermined Significance | Smoldering MyelomaFrance
-
Fondation FondaMentalRecruiting
-
National Cheng-Kung University HospitalCompleted
-
Mayo ClinicCompleted
-
Mansoura University HospitalUnknown
-
Sheri Kashmir Institute of Medical SciencesUniversity of Pennsylvania; Indian Heart Rhythm Society; Sri Jayadeva Institute...Active, not recruitingVentricular Tachycardia | Sudden Cardiac Death | Arrhythmogenic Right Ventricular Cardiomyopathy | Arrhythmogenic Right Ventricular Dysplasia | Arrhythmogenic Ventricular Cardiomyopathy | Arrhythmogenic CardiomyopathyUnited States, India